Novogen drug acts on prostate cancer
Tuesday, 23 November, 2004
Novogen (ASX: NRT) subsidiary Marshall Edwards (LSE AIM: MSH, Nasdaq: MSHL) has reported that its lead drug phenoxodiol can slow down the progression of hormone refractory prostate cancer.
The results from a Phase Ib/IIa study of the drug in men with advanced metastatic disease were reported at the American Association of Cancer Research conference in Florida last week.
The dose response study showed that at the higher doses, the drug slowed the progression of disease and affected PSA levels over a period of 6-18 months, with no apparent toxicity, suggesting that the drug exerted an anti-tumour effect.
The company is planning a Phase IIb/IIIa multicentre international clinical trial to further test the drug in men with hormone refractory prostate cancer.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
